Journal: medRxiv
Article Title: A liquid biopsy-centered, pan-cancer, open next generation sequencing panel to support clinical decision-making (LION panel)
doi: 10.64898/2026.06.05.26354976
Figure Lengend Snippet: (A) Longitudinal comparison of BRAF V600E detection in liquid biopsy samples from the melanoma patient using ddPCR and NGS (VarDict filter). In NGS analysis, the baseline value represents the average of two technical replicates. (B) Overview of sample collection, treatments and disease stages for the melanoma patient. Time points are indicated as weeks after initial diagnosis. Disease stage was determined clinically according to the AJCC classification (2009). Metastasis indicates the presence and location of metastases. All samples are liquid biopsies (cfDNA). (C) Longitudinal dynamics of mutations detected by the LION panel in liquid biopsy samples from the melanoma patient. The baseline sample consists of two technical replicates. Only mutations with a VAF <40% across all samples are shown. The 9 mutations with the highest VAF (>1%) are labeled. For additional details, see Supplementary Figure S7. (D) Overview of sample collection and genetic analyses for the rectal cancer patient in relation to clinical status. Timepoints indicate months after recurrence. Clinical events were assessed by imaging (MRI/CT): “Regression” = tumor regression observed; “Suspected progression” = possible disease progression based on clinical findings (suspicious presacral and pulmonary lesions, as well as suspicious mediastinal and para-iliac lymph nodes). (E) Mutations identified in tumor tissue by WES that were also detectable by the LION panel. The baseline liquid biopsy sample was collected one month after surgery for tumor recurrence; FU1 and FU2 were collected five and nine months later, respectively (see ). (F) Longitudinal dynamics of mutations detected by the LION panel in liquid biopsy samples from the rectal cancer patient. Only mutations with a VAF <30% across all samples are shown. The 8 mutations with the highest VAF (>2%) are labeled. For additional details, see Supplementary Table S11B and Figure S8. cfDNA, cell-free DNA; ddPCR, digitaldroplet polymerase chain reaction; FU, follow-up; NGS, next generation sequencing; TRA, translocation; VAF, variant allele frequency; WES, whole exome sequencing.
Article Snippet: Peripheral blood samples were collected in EDTA (Sarstedt, Nümbrecht, Germany) or cell-free DNA-BCT® CE tubes (Streck, La Vista, USA) and processed according to the manufacturer’s instructions as detailed in the Supplementary Methods.
Techniques: Comparison, Biomarker Discovery, Labeling, Imaging, Polymerase Chain Reaction, Next-Generation Sequencing, Translocation Assay, Variant Assay, Sequencing
Streck Laboratories is a verified supplier 
Streck Laboratories manufactures this product 
